No Data
China Health (301408.SZ): The application for the registration and marketing authorization of Sacubitril/Valsartan Sodium Tablets has been accepted.
Hua Ren Health (301408.SZ) announced that its wholly-owned subsidiary Jiangsu Shenhua Pharmaceutical Co., Ltd. has received the national pharmaceutical...
Insiders Were the Biggest Winners as Anhui Huaren Health Pharmaceutical Co., Ltd.'s (SZSE:301408) Market Cap Grew by CN¥508m Last Week
China Health (301408.SZ) shareholder SAF Investment completed a 1% shareholding reduction.
Chinese health (301408.SZ) announced that the shareholder of the company, Suzhou Saifupuxin Medical Health Industry Investment Center (Limited...
Huaren Health (301408.SZ): ali health plans to reduce its shareholding by no more than 12 million shares.
On November 22, Gelonghui reported that China Health (301408.SZ) announced that shareholder ali health technology (china) limited (referred to as "ali health") holds 30,049,373 shares of the company, accounting for 7.51% of the company's total share capital. Ali health plans to reduce its shareholding by no more than 12,000,300 shares within three months from fifteen trading days after the announcement is disclosed, through centralized bidding or block trading.
Chinese Health: Report for the third quarter of 2024
Huaren Health (301408.SZ) released its performance for the first three quarters, with a net income of 0.108 billion yuan, an increase of 22.62%.
Huaren Health (301408.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters reaching 3...
Could The Market Be Wrong About Anhui Huaren Health Pharmaceutical Co., Ltd. (SZSE:301408) Given Its Attractive Financial Prospects?
